These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 33657403)

  • 1. Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis.
    Akao M; Yasuda S; Kaikita K; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H
    Am Heart J; 2021 Jun; 236():59-68. PubMed ID: 33657403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic Therapy for Atrial Fibrillation and Coronary Artery Disease in Patients With Prior Atherothrombotic Disease: A Post Hoc Analysis of the AFIRE Trial.
    Matsuzawa Y; Kimura K; Yasuda S; Kaikita K; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Hirayama A; Matsui K; Ogawa H;
    J Am Heart Assoc; 2021 Nov; 10(21):e020907. PubMed ID: 34658247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.
    Yasuda S; Kaikita K; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H;
    N Engl J Med; 2019 Sep; 381(12):1103-1113. PubMed ID: 31475793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivaroxaban Monotherapy in Patients With Atrial Fibrillation After Coronary Stenting: Insights From the AFIRE Trial.
    Matoba T; Yasuda S; Kaikita K; Akao M; Ako J; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H;
    JACC Cardiovasc Interv; 2021 Nov; 14(21):2330-2340. PubMed ID: 34736731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atrial fibrillation and ischemic events with rivaroxaban in patients with stable coronary artery disease (AFIRE): Protocol for a multicenter, prospective, randomized, open-label, parallel group study.
    Yasuda S; Kaikita K; Ogawa H; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K
    Int J Cardiol; 2018 Aug; 265():108-112. PubMed ID: 29764706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivaroxaban Underdose for Atrial Fibrillation with Stable Coronary Disease: The AFIRE Trial Findings.
    Arashi H; Yamaguchi J; Hagiwara N; Yasuda S; Kaikita K; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Kimura K; Hirayama A; Matsui K; Ogawa H;
    Thromb Haemost; 2022 Sep; 122(9):1584-1593. PubMed ID: 35697255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bleeding and Subsequent Cardiovascular Events and Death in Atrial Fibrillation With Stable Coronary Artery Disease: Insights From the AFIRE Trial.
    Kaikita K; Yasuda S; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H
    Circ Cardiovasc Interv; 2021 Nov; 14(11):e010476. PubMed ID: 34474583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial.
    Naito R; Miyauchi K; Yasuda S; Kaikita K; Akao M; Ako J; Matoba T; Nakamura M; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H;
    JAMA Cardiol; 2022 Aug; 7(8):787-794. PubMed ID: 35704345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspirin versus P2Y
    Fukaya H; Ako J; Yasuda S; Kaikita K; Akao M; Matoba T; Nakamra M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H
    Heart; 2021 Nov; 107(21):1731-1738. PubMed ID: 34261738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.
    Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M
    JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban Monotherapy in Atrial Fibrillation and Stable Coronary Artery Disease Across Body Mass Index Categories.
    Ishii M; Kaikita K; Yasuda S; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H; Tsujita K;
    JACC Asia; 2022 Dec; 2(7):882-893. PubMed ID: 36713761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic therapy for stable coronary artery disease and atrial fibrillation in patients with and without revascularisation: the AFIRE trial.
    Noda T; Nochioka K; Kaikita K; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H; Yasuda S; Afire Investigators OBOT
    EuroIntervention; 2024 Apr; 20(7):e425-e435. PubMed ID: 38562065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety.
    Hiatt WR; Bonaca MP; Patel MR; Nehler MR; Debus ES; Anand SS; Capell WH; Brackin T; Jaeger N; Hess CN; Pap AF; Berkowitz SD; Muehlhofer E; Haskell L; Brasil D; Madaric J; Sillesen H; Szalay D; Bauersachs R
    Circulation; 2020 Dec; 142(23):2219-2230. PubMed ID: 33138628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Connolly SJ; Eikelboom JW; Bosch J; Dagenais G; Dyal L; Lanas F; Metsarinne K; O'Donnell M; Dans AL; Ha JW; Parkhomenko AN; Avezum AA; Lonn E; Lisheng L; Torp-Pedersen C; Widimsky P; Maggioni AP; Felix C; Keltai K; Hori M; Yusoff K; Guzik TJ; Bhatt DL; Branch KRH; Cook Bruns N; Berkowitz SD; Anand SS; Varigos JD; Fox KAA; Yusuf S;
    Lancet; 2018 Jan; 391(10117):205-218. PubMed ID: 29132879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombocytopenia as a Bleeding Risk Factor in Atrial Fibrillation and Coronary Artery Disease: Insights From the AFIRE Study.
    Iijima R; Tokue M; Nakamura M; Yasuda S; Kaikita K; Akao M; Ako J; Matoba T; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H;
    J Am Heart Assoc; 2023 Oct; 12(20):e031096. PubMed ID: 37815031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
    Bansilal S; Bloomgarden Z; Halperin JL; Hellkamp AS; Lokhnygina Y; Patel MR; Becker RC; Breithardt G; Hacke W; Hankey GJ; Nessel CC; Singer DE; Berkowitz SD; Piccini JP; Mahaffey KW; Fox KA;
    Am Heart J; 2015 Oct; 170(4):675-682.e8. PubMed ID: 26386791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial.
    Sherwood MW; Cyr DD; Jones WS; Becker RC; Berkowitz SD; Washam JB; Breithardt G; Fox KA; Halperin JL; Hankey GJ; Singer DE; Piccini JP; Nessel CC; Mahaffey KW; Patel MR
    JACC Cardiovasc Interv; 2016 Aug; 9(16):1694-702. PubMed ID: 27539689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Risk Factors of Thromboembolic and Major Bleeding Events for Patients with Atrial Fibrillation Treated with Rivaroxaban in Japan.
    Miyamoto S; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Minematsu K; Murakawa Y; Iwashiro S; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
    J Stroke Cerebrovasc Dis; 2020 Apr; 29(4):104584. PubMed ID: 31983518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI.
    Gibson CM; Mehran R; Bode C; Halperin J; Verheugt FW; Wildgoose P; Birmingham M; Ianus J; Burton P; van Eickels M; Korjian S; Daaboul Y; Lip GY; Cohen M; Husted S; Peterson ED; Fox KA
    N Engl J Med; 2016 Dec; 375(25):2423-2434. PubMed ID: 27959713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial.
    Li Y; Jing Q; Wang B; Wang X; Li J; Qiao S; Chen S; Angiolillo DJ; Han Y
    Am Heart J; 2020 Oct; 228():1-7. PubMed ID: 32739652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.